Login to Your Account

Onyx's Shares Drop On Top-Line Results Of Nexavar In Melanoma

By Karen Pihl-Carey

Tuesday, December 5, 2006
A Phase III failure of Nexavar in advanced melanoma thumped Onyx Pharmaceuticals Inc.'s stock by more than 30 percent Monday. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription